Neuromuscular Disorders

Phase II and III studies of CNM-Au8 in ALS 1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman • 13 Oct 2021
Myopathies and gastrointestinal involvement 1:23
Myopathies and gastrointestinal involvement
Marianne de Visser • 28 Sep 2021
Challenges in developing gene-based therapies for neurodegenerative & neuromuscular diseases 3:04
Challenges in developing gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
Approved gene-based therapies for neuromuscular diseases 3:57
Approved gene-based therapies for neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
RNA- and DNA- based therapies for neurodegenerative & neuromuscular diseases 13:42
RNA- and DNA- based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
Gene-based therapies for neurodegenerative & neuromuscular diseases 3:23
Gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
Differential diagnosis from limb-girdle muscular dystrophies 2:11
Differential diagnosis from limb-girdle muscular dystrophies
Marianne de Visser • 28 Sep 2021
How does C9orf72 expansion impact protein degradation pathways in FTLD and ALS? 4:02
How does C9orf72 expansion impact protein degradation pathways in FTLD and ALS?
Annakaisa Haapasalo • 16 Sep 2021
A novel genetic marker to detect C9orf72 repeat expansion carriers 3:43
A novel genetic marker to detect C9orf72 repeat expansion carriers
Annakaisa Haapasalo • 16 Sep 2021
Outcome measures in motor neuron diseases and neuropathies 3:03
Outcome measures in motor neuron diseases and neuropathies
Marianne de Visser • 28 Sep 2021
Novel outcome measures for ALS and SMA 3:26
Novel outcome measures for ALS and SMA
Marianne de Visser • 28 Sep 2021
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS 6:05
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS
Neil Cashman • 2 Aug 2021
Therapeutic targeting of the safety factor in myasthenic syndromes 2:44
Therapeutic targeting of the safety factor in myasthenic syndromes
Hakan Cetin • 23 Jun 2021
Exciting developments in the neuromuscular field 1:52
Exciting developments in the neuromuscular field
Gabriele Siciliano • 15 Jun 2021
Research needs in seronegative myasthenia gravis 1:37
Research needs in seronegative myasthenia gravis
Hakan Cetin • 23 Jun 2021
Safety factor at the neuromuscular junction 3:17
Safety factor at the neuromuscular junction
Hakan Cetin • 23 Jun 2021
The content of VJNeurology is intended for healthcare professionals